patisiran sodium
SpainDrugs containing this active substance
-
It is used to treat a hereditary disease called hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis), which is caused by problems with a protein called transthyretin (TTR). The medication helps reduce the amount of this protein produced by the liver to decrease the effects of the disease.
Form: solution for infusion, concentrate
Active substance Dosage patisiran sodium 10,5 mg Manufacturer: Alnylam Netherlands B.V.